



Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis

Richard P. Ramonell¹ · Imran H. Iftikhar¹

Received: 21 August 2019 / Accepted: 16 December 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

Background Several new treatments for severe asthma have become available in the last decade; yet, little data exist to guide their use in specific patient populations.

Objective A network meta-analysis was conducted comparing the efficacy of FDA-approved monoclonal antibody therapies in preventing exacerbations in patients with severe eosinophilic asthma.

Methods PubMed and Ovid were searched from inception until July 2019 for randomized controlled trials that studied the efficacy of benralizumab, dupilumab, mepolizumab, and reslizumab, in preventing acute exacerbations of asthma. Studies were included if they reported data for patients with severe eosinophilic asthma (defined in this meta-analysis as absolute eosinophil count ≥ 250 cells/ μ L). Annualized rate ratios for asthma exacerbations (during treatment) were calculated and converted to log rate ratios. Direct and indirect treatment estimates (for inter-drug differences) were analyzed using frequentist network meta-analysis methodology in R and treatments were ranked based on *P*-scores.

Results In total, nine studies were included in the final analysis. Network meta-analysis revealed that all drugs were superior to placebo in preventing rates of asthma exacerbation in the study population and no inter-drug differences existed. Dupilumab was found to have the greatest magnitudes of effect on decreasing log rate ratio of asthma exacerbation based on *P*-score (0.83).

Conclusion Benralizumab, dupilumab, mepolizumab, and reslizumab are all associated with decreased asthma exacerbations in patients with eosinophilic asthma, with no significant inter-drug differences.

Keywords Eosinophilic asthma · Benralizumab · Dupilumab · Mepolizumab · Reslizumab

Introduction

Anti-interleukin (IL)5, anti-IL5 receptor (IL-5R), and anti-IL4R have now been officially incorporated into GINA 2019 guidelines [1] as add-on controller medications for difficult-to-treat and severe asthma with type-2 inflammatory phenotypes. Type-2 inflammation, found in ~50% of severe asthma phenotypes, is primarily driven by the production of IL-4, IL-5, and IL-13, by type 2 helper T cells

(Th2), type 2 innate lymphoid cells and by the production of epithelial cell-derived alarmins such as thymic stromal lymphopoietin (TSLP). Increased sputum ($\geq 2\%$) or blood eosinophils (≥ 150 cells/ μ L), as well as fractional exhaled nitric oxide (FeNO) ≥ 20 ppb, characterizes type-2 inflammation and even though these are criteria that have been primarily used to exclude non-eosinophilic asthma (rather than confirm eosinophilic asthma), these markers have been useful to guide treatment for eosinophilic asthma [1, 2]. Mepolizumab, reslizumab, benralizumab, and dupilumab are currently approved for treatment of severe eosinophilic asthma.

Although these drugs have not been compared in a direct head-to-head randomized controlled trial (RCT), network meta-analyses have attempted to compare the relative efficacy these drugs, but with inconsistent results, especially with regard to their effects on decreasing asthma exacerbations [3–6]. Two of these network meta-analyses [4, 6]

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00408-019-00310-8>) contains supplementary material, which is available to authorized users.

✉ Imran H. Iftikhar
imran.hasan.iftikhar@emory.edu

¹ Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Department of Medicine, Emory University School of Medicine, 613 Michael St, NE, Atlanta, GA, USA

ranked reslizumab and mepolizumab as superior, another [5] only ranked mepolizumab, while another [3] ranked both reslizumab and dupilumab as superior (as compared to others for asthma exacerbations). The discordant results could be from the differences in the inclusion criteria for RCTs in these meta-analyses or the differences could have resulted from not accounting for follow-up duration or analyzing incidence density ratios for exacerbations. Since RCTs varied in their definitions for ‘eosinophilic asthma’—i.e., some [7] used blood eosinophil count cut-off of 300 cells/ μ L, some others [8] used 150 cells/ μ L, or 450 cells/ μ L [9], as well as varied in their study durations, lumping all RCTs in a meta-analysis with heterogeneous study populations could have led to inconsistent conclusions. This meta-analysis aimed to study the effects of most FDA-approved biologics (benralizumab, dupilumab, mepolizumab, and reslizumab) in decreasing asthma exacerbations in a well-defined population, with similar or almost similar baseline characteristics using person-time incidence rates, to allow for a fair comparison amongst the new biologic drugs.

Methods

The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Search Strategy and Study Eligibility Criteria

PubMed and Ovid were searched from inception to July 2019 (Fig. 1). Inclusion criteria for our meta-analysis included (a) studies had to be RCTs, (b) published in only English language, (c) RCTs studying eosinophilic asthma patient population (eosinophilic asthma population defined in our meta-analysis as those with mean baseline blood eosinophil count ≥ 250 cells/ μ L), aged 12 years or older, and in study participants who had been on medium-to-high dose inhaled corticosteroids prior to intervention and who had shown ≥ 1 asthma exacerbation in the 6 to 12 months prior to enrollment in the RCT, (d) RCTs studying benralizumab, dupilumab, mepolizumab, and reslizumab, as the drugs of




Fig. 1 Selection of studies. Details on studies excluded as shown in figure are provided in Appendix/Data Supplement

intervention, and (e) RCTs had to report data on asthma exacerbation for patients on drug and placebo during the intervention period. It was decided a priori to exclude the studies on omalizumab as they did not report data based on blood eosinophil count. For our meta-analysis, clinical asthma exacerbations were defined as a worsening of asthma that resulted in corticosteroid treatment, emergency department or urgent care, or hospitalization and expressed as events per patient-year of exposure, to adjust for differences in observation time between studies (reported in Appendix Table E1). Studies were excluded from meta-analysis if the drug was studied at experimental doses that are now not used in clinical practice (reasons for exclusion of excluded studies reported in Table E2). We strictly adhered to the inclusion criteria as defined above to ensure that the study population for this meta-analysis was similar enough in baseline characteristics across all studies (included in this meta-analysis). Two reviewers (IH and RR) independently screened the titles and abstracts of all publications and resolved any issues of disagreement through consensus.

Data Extraction and Synthesis

Data extracted from studies included first author's name, publication year, study design, population characteristics, treatments, length of follow-up, person-years, number of asthma exacerbations on treatment or on placebo. The studies were assessed for 'study quality' based on modified Cochrane methods. Data were first extracted on Microsoft Excel sheets and then on the working sheets of Comprehensive Meta-Analysis (CMA version 2.2.064; Biostat, Englewood, NJ, USA) software. Where rate ratios with 95% confidence intervals (CIs) were provided, data were used as such from those studies, and in studies where these data were not reported as such, rate ratios were calculated using reported event rate and person-years in CMA software. Relative risks reported for 52 weeks were converted into annualized rate ratios. For benralizumab, data were extracted for the 30 mg every 8 weeks regimen for both studies [7], whereas for dupilumab data were extracted for 30 mg subcutaneously every 2 weeks for 3 studies [10–12] and 30 mg subcutaneously every week for 1 study [13]. Reslizumab dosing regimen in the study [14] included in this meta-analysis was 3 mg/kg intravenously every 4 weeks. Mepolizumab dosing regimen in the 2 studies [15, 16] included in this meta-analysis was 100 mg subcutaneously every 4 weeks. Rate ratios and calculated standard errors were pooled in CMA using random effects methods and data were converted into log of rate ratios for plotting on a graphical scale. Log data were then imported into R and network meta-analysis was conducted using package 'netmeta' [17] (details in Appendix). Heterogeneity was assessed with I^2 index in direct pairwise analyses.

Results

From the initial search of 26 studies, a total of 9 studies [7, 10–16, 18] were included in our meta-analysis for quantitative data synthesis (Fig. 1). Appendix Table E2 lists the reasons for excluding other studies. The total study population consisted of 3089 study participants (1566 receiving drug and 1523 receiving placebo) and their baseline demographics are reported in Table 1. Study duration ranged from 12 to 56 weeks.

Direct Pairwise Meta-analysis

Figure 2 shows the direct pairwise meta-analysis estimates of log rate ratios for all drug classes (computed in CMA). Compared to placebo the log rate ratios (and their 95% CIs) for benralizumab, dupilumab, mepolizumab, and reslizumab were -0.52 [$(-0.90$ to $-0.14)$, I^2 72%], -1.02 [$(-1.65$ to $-0.39)$, I^2 73%], -0.80 [$(-0.98$ to $-0.61)$, I^2 0%], and -0.77 [$(-1.00$ to $-0.55)$, I^2 0%], respectively. Sensitivity analysis by selectively excluding one study [13] (which studied a dosing regimen different from the rest of the studies in the drug class) from the overall analysis did not alter the significance of the pooled analysis (e-Fig. 1).

Network Meta-analysis Estimates

Figure 3 shows the network evidence graph, which is a network laid out in two-dimensional plane, in which the nodes in the graph layout corresponded to the drug class and connecting lines displaying the treatment comparisons (thickness of lines indicating number of studies in each comparison). Table 2 (league table) presents the network meta-analysis estimates for inter-drug differences in log rate ratios for asthma exacerbations (calculated using R). The results are arranged in hierarchical and ranking order. While all drugs were superior to placebo, no inter-drug differences existed. Table 3, which is a comparison of direct and indirect treatment estimates (log rate ratios) to check for consistency of network meta-analysis, shows that no inconsistency existed in analyses. Corresponding forest plot for network meta-analysis is presented in Appendix (e-Fig. 2). Even though no inter-drug differences existed, based on the magnitude of effect (decreased log rate ratio for asthma exacerbation), ranking of treatments based on P -scores showed the following order: dupilumab, mepolizumab, reslizumab, and benralizumab (Table 4). A comparison-adjusted funnel plot did not show any statistical evidence of plot asymmetry, based on Egger's test, Begg and Mazumdar rank correlation test, and the Thompson–Sharp tests (Fig. 4).

Table 1 Baseline characteristics of study participants

Study ID (first author year published)	Duration of treatment (weeks)	N (randomized to in eosinophilic asthma patients and placebo)	Age (mean ± SD) or mean (range)	Gender (% males)	Baseline FEV ₁ (in L or % predicted and mean ± SD)	Drug dose	Blood eosinophil count threshold for inclusion criteria	Similarity in inclusion criteria (asthma exacerbation history and inhaler use)
Benralizumab								
Bleecker 2016 [7]	48	Drug: 267	Drug: 47.6 (14.6)	Drug: 35%	Drug: 1.66 (0.57)	30 mg intramuscularly q 8w	≥ 300 cells/μL	Ex: ≤ 2 in last year
		Plc: 267	Plc: 48.6 (14.7)	Plc: 33%	Plc: 1.65 (0.58)			Baseline treatment: medium–high dose ICS–LABA Ex: ≤ 2 in last year
Fitzgerald 2016 [6]	56	Drug: 239	Drug: 49.6 (13)	Drug: 42%	Drug: 1.75 (0.62)	30 mg intramuscularly q 8w	≥ 300 cells/μL	Baseline treatment: medium–high dose ICS–LABA Ex: ≤ 2 in last year
		Plc: 248	Plc: 48.5 (14.1)	Plc: 42%	Plc: 1.81 (0.64)			Baseline treatment: medium–high dose ICS–LABA
Dupilumab								
Castro 2018 [10]	52	Drug: 277	Drug: 47.7 (15.6)	Drug: 38%	Drug: 1.78 (0.60)	300 mg subcutaneously q 2w	≥ 300 cells/μL	Ex: > 1 in the last year
		Plc: 142	Plc: 48.2 (14.7)	Plc: 32%	Plc: 1.75 (0.57)			Baseline treatment: medium–high dose ICS–LABA + 2 add-on controllers Ex: not specified
Rabe 2018 [11]	24	Drug: 48	Drug: 51.9 (12.5)	Drug: 40%	Drug: 1.53 (0.53)	300 mg subcutaneously q 2w	≥ 300 cells/μL	Baseline treatment: high dose ICS + 2 controllers + maintenance steroids Ex: > 1 in the last year
		Plc: 41	Plc: 50.7 (12.8)	Plc: 39%	Plc: 1.63 (0.61)			Baseline treatment: medium–high dose ICS–LABA Ex: > 1 in the last year
Wenzel 2016 [12]	24	Drug: 64	48.6 (13) (Overall population)	37% (Overall population)	1.84 (0.54) (Overall population)	300 mg subcutaneously q 2w	≥ 300 cells/μL	Baseline treatment: medium–high dose ICS–LABA Ex: > 1 in the last year
		Plc: 68						Baseline treatment: medium–high dose ICS–LABA Ex: > 1 in the last year
Wenzel 2013 [13]	12	Drug: 52	Drug: 37.8 (13.2)	Drug: 50%	Drug: 2.47 (0.65)	300 mg subcutaneously q 1w	≥ 300 cells/μL	Baseline treatment: medium–high dose ICS–LABA Ex: > 1 in the last year
		Plc: 52	Plc: 41.6 (13.1)	Plc: 50%	Plc: 2.54 (0.66)			Baseline treatment: medium–high dose ICS–LABA
Reslizumab								
Castro 2015 [14]	48	Drug: 151 (pooled)	Study 1	Study 1	Study 1	3 mg/kg intravenously q 4w	≥ 400 cells/μL	Ex: > 1 in the last year

Table 1 (continued)

Study ID (first author year published)	Duration of treatment (weeks)	N (randomized to in eosinophilic asthma patients and placebo)	Age (mean $\pm$ SD) or mean (range)	Gender (% males)	Baseline FEV ₁ (in L or % predicted and mean $\pm$ SD)	Drug dose	Blood eosinophil count threshold for inclusion criteria	Similarity in inclusion criteria (asthma exacerbation history and inhaler use)
Mepolizumab Chupp 2017 [15]	24	Drug: 274 Plc: 237 (pooled)	Drug: 48 (38–57) Plc: 49 (38–57) Study 2 Drug: 48 (37–56.2) Plc: 48 (39.5–57)	Drug: 42% Plc: 34% Study 2 Drug: 38% Plc: 35%	Drug: 1.89 (0.73) Plc: 1.93 (0.80) Study 2 Drug: 2.13 (0.78) Plc: 2.00 (0.67)	100 mg subcutaneously q 4w	≥ 300 cells/ μ L* (in the ITT placebo and drug groups, the baseline eosinophil counts were 350 cells/ μ L, respectively)	Baseline treatment: medium dose ICS with or without another controller drug Ex: ≥ 2 in the last year
Ortega 2014 [16]	32	Drug: 194 Plc: 277	Drug: 51 (12–81) Plc: 52.1 (12.9)	Drug: 60% Plc: 36%	Drug: 1.73 (0.66) Plc: 1.7 (0.6)	100 mg subcutaneously q 4w	≥ 300 cells/ μ L* (at randomization actual mean baseline eosinophil counts were 320 cells/ μ L in placebo and 290 cells/ μ L in drug groups)	Baseline treatment: high dose ICS + additional controller drug Ex: ≥ 2 in the last year
		Plc: 191	Plc: 49 (12–76)	Plc: 56%	Plc: 1.86 (0.63)			Baseline treatment: high dose ICS + additional controller drug

N number of study participants randomized to in eosinophilic asthma patients analyzed in this meta-analysis and placebo, SD standard deviation, FEV₁ forced expiratory volume in 1 s, Plc placebo group, q 'every', w weekly, *count in the last 12 months prior to inclusion, Ex number of asthma exacerbations prior to participants enrolling in study, ICS inhaled corticosteroids, LABA long acting bronchodilator

Table 2 League table for differences in log rate ratio of asthma exacerbations

Dupilumab	–	–	–	–0.97 [–1.39; –0.56]*
–0.16 [–0.76; 0.44]	Mepolizumab	–	–	–0.81 [–1.24; –0.38]*
–0.19 [–0.91; 0.53]	–0.03 [–0.76; 0.69]	Reslizumab	–	–0.78 [–1.37; –0.19]*
–0.45 [–1.06; 0.15]	–0.29 [–0.90; 0.32]	–0.26 [–0.99; 0.47]	Benralizumab	–0.52 [–0.95; –0.09]*
–0.97 [–1.39; –0.56]*	–0.81 [–1.24; –0.38]*	–0.78 [–1.37; –0.19]*	–0.52 [–0.95; –0.09]*	Placebo

League table for random effects model with network estimates in lower triangle and direct estimates in upper triangle

*Statistically significant. Example to interpret this table: difference between dupilumab and mepolizumab is –0.16 [–0.76; 0.44]; between dupilumab and reslizumab is –0.19 [–0.91; 0.53]




Fig. 2 Meta-analysis of pooled log rate ratios for asthma exacerbations. The size of the square indicates the weight of the effect size as determined by the number of studies and participants. *CI* confidence interval




Fig. 3 Network evidence graph. Graph plotted on a two-dimensional plane, in which the connecting lines between treatment names display the treatment comparisons (thickness of lines indicating number of studies in each comparison)

Table 3 Comparison of direct and indirect treatment estimates

Comparison	k	prop	nma	Direct	Indirect
Benralizumab:dupilumab	0	0	0.45	–	0.45
Benralizumab:mepolizumab	0	0	0.29	–	0.29
Benralizumab:placebo	2	1.00	–0.52	–0.52	–
Benralizumab:reslizumab	0	0	0.26	–	0.26
Dupilumab:mepolizumab	0	0	–0.16	–	–0.16
Dupilumab:placebo	4	1.00	–0.97	–0.97	–
Dupilumab:reslizumab	0	0	–0.19	–	–0.19
Mepolizumab:placebo	2	1.00	–0.81	–0.81	–
Mepolizumab:reslizumab	0	0	–0.03	–	–0.03
Placebo:reslizumab	1	1.00	0.78	0.78	–

A comparison of direct and indirect treatment estimates (log rate ratios) to check for consistency of network meta-analysis comparison

k Number of studies providing direct evidence, *prop* direct evidence proportion, *nma* estimated treatment effect in network meta-analysis, *direct* estimated treatment effect derived from direct evidence, *indirect* estimated treatment effect derived from indirect evidence

Table 4 Ranking of treatments

	<i>P</i> -score
Dupilumab	0.83
Mepolizumab	0.66
Reslizumab	0.62
Benralizumab	0.36
Placebo	0.00

P-scores are based solely on the point estimates and standard errors of the network estimates

Discussion

With regards to their comparative effectiveness in reducing asthma exacerbations, this network meta-analysis shows no significant inter-drug differences between benralizumab, dupilumab, mepolizumab, and reslizumab. Although the conclusion is based only on 9 studies in total, the results suggest that dupilumab may have a role in the treatment of eosinophilic asthma and should be compared to mepolizumab, reslizumab, and benralizumab in a direct, RCT.

This network meta-analysis differs from the previously published network meta-analyses. In the network meta-analysis by Casale et al. [19], only benralizumab and reslizumab studies were analyzed, and in the matching-adjusted indirect comparison meta-analysis by Bourdin et al. [20], only benralizumab, reslizumab, and mepolizumab were analyzed. In the network meta-analyses by

Cabon et al. [6] and He et al. [4], only benralizumab, reslizumab, and mepolizumab were compared. While the former [6] attempted to analyze data separately for those with eosinophilic asthma, not all included studies had a uniform criteria for defining eosinophilic asthma [21], as such ‘clinical asthma exacerbation’ was not an ‘a priori’ defined outcome in the meta-analysis, and the analysis incorporated data from studies with drug dosing that is not clinically used (e.g., studying mepolizumab at 75 mg, 250 mg, and 750 mg doses). In the network meta-analysis by He et al. [4], not only was ‘eosinophilic asthma’ or ‘clinical asthma exacerbation’ defined a priori, incidence density rates (using person-time) were not reported, and drugs with irrelevant clinical dosing were used (e.g., studying mepolizumab at 75 mg, 250 mg and 750 mg doses, and combining benralizumab 0.3 mg/kg with other doses). The indirect treatment comparison by Busse et al. [5] did compare the licensed doses of benralizumab, mepolizumab, and reslizumab and adequately defined ‘clinical asthma exacerbation,’ as well as parsed out the data based on different blood eosinophil counts. This network meta-analysis resembles the meta-analysis by Busse et al. in having stringent inclusion criteria for studies but differs in some other respects: (1) this meta-analysis included dupilumab studies, as well as (2) used log of rate ratios in analyses. The argument for using logarithmic scale as opposed to an arithmetic scale is taken from the policy of American Journal of Epidemiology (instructions to authors), which states, “when plotting relative measures of effect (e.g., relative risks, relative odds), a logarithmic




Fig. 4 Comparison-adjusted funnel plot. Comparison-adjusted funnel plot for publication bias assessment with statistical tests for plot asymmetry reported in top left corner

scale must be used unless there is a compelling reason to use an arithmetic scale” (<https://aje.oxfordjournals.org/>). This is because the null effect of 1.0 divides the scale into two regions that are equivalent in strength of association. For every point above 1.0, there is a corresponding inverse point below 1.0. However, visually, on an arithmetic scale, points below the null (the preventive effects below the null) are squeezed into a small region from 0 to 1 (finite scale), and the causative effects are stretched across the infinite region above 1.0. This apparent visual imbalance can be corrected if the effects are plotted on a log scale allowing for symmetry between preventive and causative effects [22, 23].

This meta-analysis has important limitations. Most notably, the inclusion criteria were made stringent a priori to ensure that the study population was as homogenous as possible. As a result, the total number of trials included was limited but the data presented are more precise because the definitions of asthma exacerbation and eosinophilic asthma were relatively consistent across the included studies. The definition of eosinophilic asthma for this study was lowered to include patients with peripheral eosinophilia ≥ 250 cells/ μL to allow inclusion of a relatively bigger study population, although more consensus definitions seem to be adopting an eosinophil blood count of ≥ 300 cells/ μL . Although this did not affect the outcome of the analysis, future meta-analyses and RCTs will need to utilize a stricter definition of eosinophilic asthma once that is established. Another limitation of this meta-analysis is that it does not capture all of the currently available biologics, most notably, omalizumab, which is a monoclonal antibody targeting the high-affinity IgE receptor (Fc ϵ RI) binding site of immunoglobulin E. Although this biologic therapy is FDA approved and has shown clinical benefits across several trials, none of the published RCTs specified ‘eosinophilic asthma’ in their inclusion criteria (which could have theoretically allowed inclusion in this network meta-analysis) [24–30]. As such, omalizumab data would have been applicable in our analysis because IgE does play a role in eosinophil biology through its interaction with mast cells. When IgE on the surface of mast cells encounters cognate antigen, it causes mast cell degranulation producing prostaglandin D₂, which is a known eosinophil chemokine via the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) [31]. Retrospective data about the efficacy of omalizumab that stratified patients into “high” and “low” eosinophil subgroups based on a blood eosinophil count ≥ 300 cells/ μL found that omalizumab has similar efficacy in patients with eosinophilic asthma as in non-eosinophilic asthma [32]. Another limitation of this meta-analysis is that we excluded all studies that evaluated drug dosing not approved by the FDA. The only exception to this rule was the inclusion of a study which administered dupilumab at a dose of 30 mg

weekly instead of every 2 weeks [13]. As such, sensitivity analysis (e-Fig. 1) by selectively excluding this study did not change the overall outcome or conclusions. We believe that the strength of the data presented outweighs the exclusion of the excluded studies (Table E2 lists the reasons for exclusion of excluded studies), but it is important to note that our analysis is not comprehensive and needs to be updated with further studies as more trials become available.

In conclusion, this meta-analysis confirms that anti-IL-5/anti-IL-5R monoclonal antibody therapies are associated with a decrease in asthma exacerbations in patients with eosinophilic asthma, almost to a similar degree. While these clinical findings are biologically plausible, our analysis highlights the need not only for a large, direct, randomized trial comparing all biologic therapies in asthma phenotypes but also reinforces the need for further study of non-anti-IL-5/anti-IL-5R biologics in eosinophilic asthma.

Author Contributions IHI had full access to all of the extracted data in the network meta-analysis and takes responsibility for the integrity of the data and the accuracy of the data analysis. IHI conceptualized and designed the study protocol, conducted the analyses and wrote the first draft manuscript. IHI and RPR contributed to assessment of study quality. Both authors contributed substantially to the interpretation of analyses and in revisions of manuscript.

Funding This study was not sponsored by any funding agency or pharmaceutical company.

Compliance with Ethical Standards

Conflicts of interest None.

References

1. <https://ginasthma.org/severeasthma/>. Accessed 4 Aug. April 2019 edition
2. Carr TF, Zeki AA, Kraft M (2018) Eosinophilic and noneosinophilic asthma. *Am J Respir Crit Care Med* 197:22–37
3. Iftikhar IH, Schimmel M, Bender W, Swenson C, Amrol D (2018) Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. *Lung* 196:517–530
4. He LL, Zhang L, Jiang L, Xu F, Fei DS (2018) Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis. *Int Immunopharmacol* 64:223–231
5. Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB (2019) Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. *J Allergy Clin Immunol* 143:190–200.e120
6. Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, Bourdin A (2017) Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. *Clin Exp Allergy* 47:129–138

7. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S et al (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 388:2128–2141
8. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M et al (2017) Oral glucocorticoid-sparing effect of benralizumab in severe asthma. *N Engl J Med* 376:2448–2458
9. Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, Fiening JP, Kim K, Molfino NA (2015) A randomized trial of benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, after acute asthma. *Am J Emerg Med* 33:14–20
10. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med* 378:2486–2496
11. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med* 378:2475–2485
12. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 388:31–44
13. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med* 368:2455–2466
14. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med* 3:355–366
15. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. *Lancet Respir Med* 5:390–400
16. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med* 371:1198–1207
17. Schwarzer G, Carpenter JR, Rücker G (2015) Meta-analysis with R. Chapter 8. Springer, Cham
18. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R (2017) Tezepelumab in adults with uncontrolled asthma. *N Engl J Med* 377:936–946
19. Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M (2019) Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis. *J Allergy Clin Immunol Pract* 7:122–130.e121
20. Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X (2018) Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. *Eur Respir J*. <https://doi.org/10.1183/13993003.01393-2018>
21. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B et al (2014) Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. *Lancet Respir Med* 2:879–890
22. Rothman KJ, Wise LA, Hatch EE (2011) Should graphs of risk or rate ratios be plotted on a log scale? *Am J Epidemiol* 174:376–377; discussion 377
23. Levine MA, El-Nahas AI, Asa B (2010) Relative risk and odds ratio data are still portrayed with inappropriate scales in the medical literature. *J Clin Epidemiol* 63:1045–1047
24. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. *Allergy* 59:701–708
25. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. *Allergy* 59:709–717
26. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J et al (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy* 34:632–638
27. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol* 108:184–190
28. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. *Allergy* 60:302–308
29. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S et al (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. *Allergy* 60:309–316
30. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W (2011) Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. *Ann Intern Med* 154:573–582
31. Singh D, Ravi A, Southworth T (2017) CRTH2 antagonists in asthma: current perspectives. *Clin Pharmacol* 9:165–173
32. Humbert M, Taille C, Mala L, Le Gros V, Just J, Molimard M, STELLAIR Investigators (2018) Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. *Eur Respir J*. <https://doi.org/10.1183/13993003.02523-2017>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

APPENDIX (DATA SUPPLEMENT)

Details on Methods:

Network meta-analysis using '*frequentist*' methods was conducted in R program version 3.6.1 (R Development Core Team), using package 'netmeta' [1]. Function 'netgraph' generated a graph of the evidence network. In this function we used the argument, '(thickness = "number.of.studies")' which created lines between two treatments that was proportional to number of studies comparing two treatments and the network graph was created 2D. Network meta-analysis results were reported in a 'league table', which is a square matrix showing all pairwise comparisons in a network meta-analysis, with network estimates in lower triangle, and direct estimates in upper triangle. Forest plots of the corresponding analyses were generated. Function 'netsplit' was used to split network estimates into the contribution of direct and indirect evidence and to test for local inconsistency in network meta-analysis. Treatments are ranked based on a network meta-analysis. Ranking is performed by P-scores. P-scores are based solely on the point estimates and standard errors of the network estimates. They measure the extent of certainty that a treatment is better than another treatment, averaged over all competing treatments. This interpretation is comparable to that of the Surface Under the Cumulative Ranking curve (SUCRA) which is the rank of treatment (*i*) within the range of treatments, measured on a scale from 0 (worst) to 1 (best) [2]. A 'comparison-adjusted' funnel plot to assess funnel plot asymmetry in network meta-analysis was constructed reporting p-values for asymmetry (for Eggers test of intercept, Begg and Mazumdar rank correlation test, and the Thompson-Sharp tests) [3].

Table E1: Clinical Asthma Exacerbation Definitions

Study ID (First author – year published)	Clinical Asthma Exacerbation Definitions
Benralizumab	
Bleecker 2016 [4]	Worsening of asthma was defined as new or increased symptoms and/or signs (examination or lung function) that could be either concerning to the patient (patient-driven) or related to an Asthma Daily Diary alert (diary-driven). Asthma Daily diary alerts were considered to be one or a combination of: 1) a decrease in morning peak flow $\geq 30\%$ on at least 2 of 3 consecutive days compared with baseline, 2) $\geq 50\%$ increase in rescue medication and/or use of one new or additional nebulized LABA on at least 2 of 3 consecutive days compared with the average use for the previous week, 3) nocturnal awakening due to asthma, requiring rescue medication use for at least 2 of 3 consecutive nights, or 4) an increase in total asthma symptom score of at least 2 units above the run-in average (last 10 days of run-in), or a score of 6 (maximum possible score) on at least 2 of 3 consecutive days or a worsening of signs or symptoms as identified by physician assessment.
Fitzgerald 2016 [5]	Worsening of asthma was defined as any new or increased symptoms or signs that were concerning to the patient or related to an Asthma Daily Diary alert. Patients' ePRO devices were programmed to alert the patient and study center when certain pre-specified worsening thresholds were crossed on ≥ 2 of 3 consecutive days/nights, including: a) Decrease in morning PEF of $\geq 30\%$ compared with baseline. (b) $\geq 50\%$ increase in rescue medication use or one new/additional nebulized β_2 -agonist compared with average use in the previous 7 days. (c) Nocturnal awakening due to asthma requiring rescue medication. (d) An increase in total asthma symptom score of two or more units above the screening average, or the maximum possible score (daily score of 6).
Dupilumab	
Castro 2018 [6]	A severe asthma exacerbation was defined as a deterioration of asthma leading to treatment for 3 days or more with systemic glucocorticoids or hospitalization or an emergency department visit leading to treatment with systemic glucocorticoids.
Rabe 2018 [7]	Severe exacerbation events defined as events leading to hospitalization, an emergency department visit, or treatment for ≥ 3 days with systemic glucocorticoids at ≥ 2 times the current dose of oral glucocorticoid
Wenzel 2016 [8]	A severe exacerbation event during the study was defined as a deterioration of asthma requiring use of systemic corticosteroids for ≥ 3 days, or hospitalization or emergency department visit because of asthma requiring systemic corticosteroids
Wenzel 2013 [9]	An exacerbation was defined as the occurrence of any one of the following: a reduction of 30% or more in morning peak expiratory flow (PEF) from baseline on 2 consecutive days, at least six additional reliever inhalations of albuterol or levalbuterol in a 24-hour period relative to baseline on 2 consecutive days, or an exacerbation of asthma requiring systemic glucocorticoid treatment, an increase in inhaled glucocorticoids of at least four times the most recent dose, or hospitalization for asthma, as determined by the investigator
Reslizumab	
Castro 2015 [10]	Clinical asthma exacerbations were defined as worsening of asthma that resulted in use of systemic corticosteroids in patients not already receiving treatment, or a two-times increase in the dose of either inhaled corticosteroids or systemic corticosteroids for 3 or more days, or the need for asthma-related emergency treatment (emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment). To be analyzed as an asthma exacerbation, these medical interventions must have been associated with a decrease in FEV1 of 20% or more from baseline, a reduction in peak expiratory flow rate by 30% or more from baseline on 2 consecutive days, or a worsening of signs or symptoms (as identified by physician assessment)
Mepolizumab	
Chupp 2017 [11]	Defined as worsening of asthma requiring systemic corticosteroids administered intravenously or orally for ≥ 3 days or as a single intramuscular dose, or an emergency room visit or admission to hospital, exacerbations requiring an emergency room visit or admission to hospital, and exacerbations requiring admission to hospital.
Ortega 2014 [12]	Defined as worsening of asthma such that the treating physician elected to administer systemic glucocorticoids for at least 3 days or the patient visited an emergency department or was hospitalized

Table E2: Reasons for exclusion of RCTs from meta-analysis

Benralizumab	
Castro 2014 [13]	Studied clinically irrelevant doses of 2mg, 20mg, and 100 mg
Laviolette 2013 [14]	1. Studied clinically irrelevant doses of 100mg or 200mg 2. Data for rate ratio not provided 3. Data not provided for eosinophilic asthma (defined in our meta-analysis as blood eosinophil count $\geq$ 250 cells per μL)
Nair 2017 [15]	Study did not provide data to calculate rate ratio for the eosinophilic asthma population (blood eosinophil count $\geq$ 300 cells per μ L)
Nowak 2015 [16]	1. Concerns about study dosing regimen and frequency of dosing 2. Data for asthma exacerbations was presented for $>$ or $<$ 300 cells per μL asthma sub-groups (separately for placebo and drug groups) but rate ratios were calculable
Ferguson 2017 [17]	Data on asthma exacerbation not specified for asthma endotype (eosinophilic or non-eosinophilic groups)
Park 2016 [18]	Studied clinically irrelevant doses of 2mg, 20mg, and 100 mg
Busse 2019 [19]	Excluded due to study design issues
Dupilumab	
Corren 2019 [20]	1. This was post-hoc analysis of an already published study 2. The study did not provide data on asthma exacerbations (or data to derive rate ratios from) 3. Eosinophilic asthma not defined
Reslizumab	
Corren 2016 [21]	1. The study did not provide data on asthma exacerbations (or data to derive rate ratios from) 2. Eosinophilic asthma sub-groups were based on the 400 cells per μL (in blood) cut-off
Bjermer 2016 [22]	1. The study did not provide data on asthma exacerbations (or data to derive rate ratios from) 2. Eosinophilic asthma sub-groups were based on the 400 cells per μL (in blood) cut-off
Castro 2011 [23]	Excluded as eosinophilia assessed by sputum count and not blood
Perez De Llano 2019[24]	Study did not provide on exacerbations
Mepolizumab	
Bel 2014 [25]	Data for asthma exacerbations not divided based on eosinophilic asthma endotype (or blood eosinophil cell counts)
Flood-Paige 2012 [26]	1. Studied clinically irrelevant dosing (250mg or 750mg intravenously) 2. Data for asthma exacerbations not divided based on eosinophilic asthma endotype (or blood eosinophil cell counts)
Haldar 2009 [27]	1. Studied clinically irrelevant dosing (750mg intravenously) 2. Data for asthma exacerbations not divided based on eosinophilic asthma endotype (or blood eosinophil cell counts)
Nair 2009 [28]	1. Studied clinically irrelevant dosing (750mg intravenously) 2. Data for asthma exacerbations not divided based on eosinophilic asthma endotype (or blood eosinophil cell counts)
Pavord 2012 [29]	1. Studied clinically irrelevant dosing (75mg, 250mg, 750mg intravenously) 2. Data for asthma exacerbations not divided based on eosinophilic asthma endotype (or blood eosinophil cell counts)

Mg indicates milligrams; μ L indicates microliters

Table E3: Assessment of study quality

Study ID (First author – year published)	Random sequence generation	Allocation concealment	Blinding of outcomes assessment	Incomplete outcome data	Selective reporting
Benralizumab					
Bleecker 2016 [5]	L	L	L	L	L
Fitzgerald 2016 [5]	L	L	L	L	L
Dupilumab					
Castro 2018 [6]	L	L	L	L	L
Rabe 2018 [7]	L	L	L	L	L
Wenzel 2016 [8]	L	L	L	U	U
Wenzel 2013 [9]	L	L	L	U	U
Reslizumab					
Castro 2015 [10]	L	L	L	U	L
Mepolizumab					
Chupp 2017 [11]	L	L	L	L	L
Ortega 2014 [12]	L	L	L	L	L

L indicates low risk
U indicates unclear risk

Table E4: MeSH and key words used for search in PubMed and Ovid

Search Terms used in PubMed	
Benralizumab	("benralizumab"[Supplementary Concept] OR "benralizumab"[All Fields]) AND ("asthma"[MeSH Terms] OR "asthma"[All Fields])
Dupilumab	("dupilumab"[Supplementary Concept] OR "dupilumab"[All Fields]) AND ("asthma"[MeSH Terms] OR "asthma"[All Fields])
Reslizumab	("reslizumab"[Supplementary Concept] OR "reslizumab"[All Fields]) AND ("asthma"[MeSH Terms] OR "asthma"[All Fields])
Mepolizumab	("mepolizumab"[Supplementary Concept] OR "mepolizumab"[All Fields]) AND ("asthma"[MeSH Terms] OR "asthma"[All Fields])
Search Terms used in Ovid	Asthma/ or benralizumab Dupilumab Reslizumab Mepolizumab Tezepelumab.mp.

AND, OR are Boolean operator terms

Table E5: PRISMA checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	https://www.crd.york.ac.uk/prospero/#recordDetails
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5, 6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Table E4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5, 6
Data collection	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining	6

process		and confirming data from investigators.	
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5, 6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Table E3
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7 (and Table 1)
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Table E3
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7, 8 and table 2-4, and figure 2, 3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7, 8 and table 2-4, and figure 2, 3
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Table E3
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	E-figure 1
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g.,	9

		healthcare providers, users, and policy makers).	
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Title page

E-Figure 1: Sensitivity analysis




Figure legend: The size of the square indicates the weight of the effect size as determined by the number of studies and participants. CI, confidence interval, and the diamond indicates the pooled effect for each sub-group of studies

E-Figure 2:




Figure legend: The size of the square indicates the weight of the direct estimate as determined by the number of studies and participants. IRD is incidence rate density which in this case is the log rate ratios; CI, confidence interval, and the diamond indicates indirect/network meta-analysis estimate

REFERENCES:

1. Schwarzer G, Carpenter JR and Rücker G: Meta-Analysis with R. Chapter 8.
2. Rucker G, Schwarzer G: Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Med Res Methodol* 2015, 15:58.
3. Chaimani A, Salanti G: Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. *Res Synth Methods* 2012, 3:161-176.
4. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V *et al*: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet* 2016, 388:2115-2127.
5. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S *et al*: Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2016, 388:2128-2141.
6. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM *et al*: Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *N Engl J Med* 2018, 378:2486-2496.
7. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A *et al*: Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. *N Engl J Med* 2018, 378:2475-2485.
8. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN *et al*: Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 2016, 388:31-44.
9. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B *et al*: Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med* 2013, 368:2455-2466.
10. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S: Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med* 2015, 3:355-366.
11. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A: Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. *Lancet Respir Med* 2017, 5:390-400.
12. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW *et al*: Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med* 2014, 371:1198-1207.
13. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B *et al*: Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. *Lancet Respir Med* 2014, 2:879-890.

14. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V *et al*: Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. *J Allergy Clin Immunol* 2013, 132:1086-1096 e1085.
15. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnambal S, Goldman M *et al*: Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. *N Engl J Med* 2017, 376:2448-2458.
16. Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, Fiening JP, Kim K, Molino NA: A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. *Am J Emerg Med* 2015, 33:14-20.
17. Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M *et al*: Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2017, 5:568-576.
18. Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, Tohda Y, Asian Benralizumab Study G: A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan. *Int Arch Allergy Immunol* 2016, 169:135-145.
19. Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, investigators Bs: Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. *Lancet Respir Med* 2019, 7:46-59.
20. Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbe A, Taniou C *et al*: Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. *Ann Allergy Asthma Immunol* 2019, 122:41-49 e42.
21. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M: Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. *Chest* 2016, 150:799-810.
22. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M: Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. *Chest* 2016, 150:789-798.
23. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P, Res-5- Study G: Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. *Am J Respir Crit Care Med* 2011, 184:1125-1132.
24. Perez de Llano LA, Cosio BG, Domingo C, Urrutia I, Bobolea I, Valero A, Entrenas Costa LM, Quirce S, Barranco P, Marina Malanda N *et al*: Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. *J Allergy Clin Immunol Pract* 2019.
25. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Investigators S: Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med* 2014, 371:1189-1197.
26. Flood-Page P, Swenson C, Faierman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT *et al*: A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. *Am J Respir Crit Care Med* 2007, 176:1062-1071.

27. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ *et al*: Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med* 2009, 360:973-984.
28. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. *N Engl J Med* 2009, 360:985-993.
29. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet* 2012, 380:651-659.